Novartis evidence on ‘step change’ Jakavi not yet enough for NICE
This article was originally published in Scrip
Novartis has so far failed to convince NICE, the health technology appraisal institute, to recommend for use on the National Health Service the firm's JAK inhibitor, Jakavi (ruxolitinib). Even though the institute recognized that Jakavi was an innovative treatment for patients with splenomegaly and myelofibrosis, there were uncertainties in the evidence, including missing data, according to draft guidance issued on 13 February. That means that a second appraisal committee must now take place on 13 March. Carole Longson, director of NICE's Health Technology Evaluation Centre urged "all those with an interest in myelofibrosis" to comment via the NICE website.